Bioeq and Zydus partners for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO® BLA has been approved by the USFDA
Latest news
Gdansk, Poland and Utrecht, The Netherlands 13th July 2020. In 2016, Polpharma Biologics acquired Dutch based Biocero...
We have developed our SPOT™ technology alongside our proprietary CHO cell line to increase the cell line specific pro...
The current situation caused by COVID-19 concerns us all. We had decided to help because we care. That’s why we have...
Dr. Louis Boon, Chief Scientific Officer of Bioceros (division of Polpharma Biologics Group), talked about Bioceros C...
First subjects in ph III study with PB006 (proposed Biosimilar to Natalizumab) have been randomized.
Our phase III clinical trial (PB006-03-01) entered into the stage when first patients were treated with study medicat...
Polpharma Biologics today announces that it has entered a global commercialization agreement with Sandoz AG for a nat...
We participated in the 32nd International Symposium on Preparative and Process Chromatography in Baltimore.